Related Experiment Video
Updated: Mar 16, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
NCCN Guidelines Insights: Melanoma, Version 3.2016
Daniel G Coit1, John A Thompson1, Alain Algazi1
1From Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Michigan Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; UC San Diego Moores Cancer Center; Fred & Pamela Buffett Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The University of Tennessee Health Science Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; University of Colorado Cancer Center; Aim at Melanoma; Vanderbilt-Ingram Cancer Center; Mayo Clinic Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Yale Cancer Center/Smilow Cancer Hospital; Fox Chase Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; The University of Texas MD Anderson Cancer Center; Duke Cancer Institute; Roswell Park Cancer Institute; Stanford Cancer Institute; Massachusetts General Hospital Cancer Center; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; and National Comprehensive Cancer Network.
Recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Melanoma reflect new data on innovative treatments. These revisions focus on systemic therapy for patients with advanced or unresectable melanoma.
Area of Science:
- Oncology
- Dermatology
- Clinical Practice Guidelines
Background:
- Melanoma treatment landscape is rapidly evolving.
- Emerging data necessitates guideline updates.
- Current guidelines require revision for metastatic and unresectable melanoma.
Purpose of the Study:
- To summarize recent revisions to the NCCN Guidelines for Melanoma.
- To present the data supporting changes in systemic therapy recommendations.
- To provide rationale for updated treatment strategies.
Main Methods:
- Review of emerging clinical trial data.
- Analysis of novel agents and treatment regimens.
- Synthesis of evidence for guideline development.
Main Results:
- Significant revisions to NCCN Guidelines for Melanoma systemic therapy.
- Inclusion of new data on novel agents.
- Updated recommendations for metastatic and unresectable melanoma.
Conclusions:
- NCCN Guidelines for Melanoma have been substantially updated.
- Evidence supports changes in systemic therapy for advanced melanoma.
- Guidelines reflect the latest advancements in melanoma treatment.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:14Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:19Standards of Care II
02:56Treatment Resistent Cancers